Stockscreener 앱 받기
1.48
0.00%
0.00
시간 외 거래:
1.50
0.02
+1.35%
전일 마감가:
$1.48
열려 있는:
$1.49
하루 거래량:
88,021
Relative Volume:
0.40
시가총액:
$4.91M
수익:
-
순이익/손실:
$-16.22M
주가수익비율:
-0.1305
EPS:
-11.3419
순현금흐름:
$-16.27M
1주 성능:
-8.07%
1개월 성능:
-5.13%
6개월 성능:
-87.06%
1년 성능:
-91.53%
1일 변동 폭
$1.4364
$1.50
1주일 범위
$1.42
$1.665
52주 변동 폭
$1.34
$23.10
Metavia Inc Stock (MTVA) Company Profile
명칭
Metavia Inc
전화
(857) 702-9600
주소
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.48 | 4.91M | 0 | -16.22M | -16.27M | -11.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
Metavia Inc 주식(MTVA)의 최신 뉴스
OTC Markets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and David Bautz, PhD, Senior Analyst at Zacks SCR - Yahoo Finance
Recap Report: What is the target price for MetaVia Inc stock2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
MetaVia Advances DA-1726 GLP-1/Glucagon Dual Agonist for Obesity With IRB Approval for Higher-Dose Phase 1 Trial - Minichart
MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3 - TipRanks
MetaVia gets IRB approval to start Phase 1 Part 3 trial of DA-1726; dosing in April, data due Q4 2026 - TradingView
MetaVia receives IRB approval for Phase 1 Part 3 trial of DA-1726 - Investing.com
MetaVia (NASDAQ: MTVA) advances DA-1726 obesity program with IRB-approved higher-dose Phase 1 trial - Stock Titan
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control - PR Newswire
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel - Indian Pharma Post
MTVA: Lead asset achieves rapid weight loss and liver benefits; pivotal data due by year-end - TradingView
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 - PR Newswire
Analysts Are Bullish on Top Healthcare Stocks: MetaVia (MTVA), Immunome (IMNM) - The Globe and Mail
US Market Wrap: Can MetaVia Inc continue delivering strong returns2025 Technical Overview & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - ChartMill
Buyout Rumor: Will MetaVia Inc outperform its industry peersMarket Sentiment Summary & Target Return Focused Picks - baoquankhu1.vn
Growth Value: How does FCCO compare to its peersJuly 2025 Review & Verified Trade Idea Suggestions - baoquankhu1.vn
MetaVia: DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year - TradingView
MetaVia: Promising early results for obesity and MASH drugs set up major 2024 data and partnership catalysts - TradingView
Dow Update: Should I invest in MetaVia Inc before earningsJuly 2025 Closing Moves & Accurate Entry/Exit Alerts - baoquankhu1.vn
MTVA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investment Recap: Is MetaVia Inc currently under institutional pressureTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Hedge Fund Bets: Why is CCNE stock going downJuly 2025 Big Picture & Community Verified Trade Signals - baoquankhu1.vn
Chart Watch: What are CIOPRAs recent SEC filings showingJuly 2025 Market Mood & Community Trade Idea Sharing Platform - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) vs. MetaVia (NASDAQ:MTVA) Head-To-Head Survey - Defense World
Aug Ideas: Should I invest in MetaVia Inc before earningsTrade Volume Summary & High Conviction Investment Ideas - baoquankhu1.vn
Trade Recap: Is now the right time to enter MetaVia IncJuly 2025 Setups & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference - PR Newswire
Can MetaVia Inc. stock outperform in a bear marketTreasury Yields & Proven Capital Preservation Methods - mfd.ru
What is the target price for MetaVia Inc. stockEarnings Summary Report & Risk Controlled Swing Alerts - mfd.ru
How MetaVia Inc. stock performs in stagflationTrade Risk Report & Fast Entry and Exit Trade Plans - mfd.ru
MetaVia secures patent protection for obesity treatment through 2041 - Investing.com India
Metavia builds comprehensive global patent protection for DA-1726, securing exclusive rights to novel obesity and metabolic therapy - marketscreener.com
Can MetaVia Inc. continue delivering strong returnsMarket Movers & Entry Point Confirmation Signals - mfd.ru
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 - PR Newswire
Will MetaVia Inc. outperform its industry peers2025 Historical Comparison & Fast Entry and Exit Trade Plans - mfd.ru
Opus Genetics, MetaVia, Enbridge - TradingView
Will MetaVia Inc. stock go up in YEAROil Prices & Real-Time Volume Surge Alerts - mfd.ru
Earnings Recap: What analysts say about MetaVia Inc. stockWeekly Investment Report & Fast Gaining Stock Strategy Reports - mfd.ru
MetaVia (MTVA) Stock Price, News & Analysis - MarketBeat
Aug Drivers: Does MetaVia Inc outperform in volatile markets2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn
Technical Analysis: Is now the right time to enter MetaVia IncJuly 2025 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
AI modeling confirms therapeutic targets for MetaVia’s vanoglipel By Investing.com - Investing.com Australia
Metavia Inc announces positive AI-modeling results from ongoing SyntekaBio collaboration, confirming key therapeutic targets for Vanoglipel - marketscreener.com
AI modeling confirms therapeutic targets for MetaVia’s vanoglipel - Investing.com
Metavia IncAnnounces Positive Ai-Modeling Results From Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets For Vanoglipel - TradingView
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel - ChartMill
Bear Alert: Is REVBW a potential multi baggerWall Street Watch & Momentum Based Trading Signals - baoquankhu1.vn
Breakout Watch: Is MetaVia Inc in a consolidation phase2025 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug EndMonth: How correlated is RNAC to the S P500July 2025 Weekly Recap & Daily Stock Trend Reports - baoquankhu1.vn
MetaVia Updates 2025 Executive Discretionary Bonus Disclosure - TipRanks
Gainers Report: What is the next catalyst for MetaVia IncWatch List & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Metavia Inc (MTVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):